Journal: Therapeutic Advances in Medical Oncology
Article Title: The clinical utility of gene expression assays in breast cancer patients with 0–3 involved lymph nodes
doi: 10.1177/17588359211038467
Figure Lengend Snippet: Selected clinical trials evaluating gene expression assays.
Article Snippet: This review will summarize the clinical utility of several commonly used multiparameter gene expression assays , including the Oncotype DX Recurrence Score (RS) (Genomic Health, Exact Sciences, Madison WI), MammaPrint (Agendia, Inc., Irvine, CA), PAM50 Risk of Recurrence (ROR) score (Prosigna, Veracyte, San Francisco, CA), EndoPredict (EP) (Myriad Genetics, Salt Lake City, UT), and Breast Cancer Index (BCI) (Biotheranostics, Inc., San Diego, CA), in early hormone receptor-positive (HR+) HER2 negative BCA.
Techniques: Clinical Proteomics, Gene Expression, Adjuvant, Comparison